Market Trends of China In Vitro Diagnostics Industry
Molecular Diagnostics Segment Dominates the Chinese In Vitro Diagnostics Market
In diagnostics research, one of the most valuable advancements has been in the form of molecular diagnostic tools. The polymerase chain reaction is at the forefront of molecular diagnostics. The real-time PCR products simultaneously detect viruses, bacteria, fungi, and parasites, allowing molecular laboratories to operate at lower costs and ensure better outcomes.
Molecular diagnostic tests look for specific sequences in DNA or RNA, such as single nucleotide polymorphisms (SNPs), deletions, rearrangements, insertions, and others, that may or may not be linked to a disease.
Molecular diagnostics were mainly used to diagnose infectious diseases, and with the rising burden and increasing spread of the COVID-19 pandemic, the segment was at its peak in the country. To find viral RNAs that are very specific to the SARS-CoV-2 virus, which caused COVID-19, molecular diagnostic tests were used.
In addition, the rising burden of infectious disease can be attributed to the segment's growth. For instance, according to the National Health Commission, nearly 1.71 million cases of infectious diseases were reported on the mainland. Approximately 288,739 cases were classified as Class B infectious diseases. Viral hepatitis, TB, syphilis, scarlet fever, and gonorrhea accounted for 94% of these cases. Thus, owing to the rising importance given by clinical laboratories to diagnose diseases in the early stages of development, collaboration with domestic manufacturers, and new product launches, the molecular diagnostics segment is expected to witness good growth over the forecast period in China.
Cancer/Oncology Segment Dominates the Chinese In Vitro Diagnostics Market
Cancer is the second-leading cause of mortality in China. Early detection of cancer and access to effective anti-cancer treatment can result in higher survival rates and a better quality of life. In vitro diagnostics (IVDs) are tests or medical devices that examine human body specimens and provide critical data for screening, diagnosis, and treatment.
The main things that are driving market segment growth in China are the rising number of people with cancer, the rising number of products being approved and put on the market, and the rising amount of money being invested.
According to the report titled "Cancer Statistics in China and the United States, 2022: Profiles, Trends, and Determinants," published in February 2022, compared to the 4,689,754 new cancer cases in China in 2020, the predicted number of new cancer cases for 2022 is 4,820,000. This increase in new cases will directly increase the demand for early diagnosis, thus helping the market grow during the study period. Also, as per the report titled "Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020," published in April 2021, China is expected to experience 6.85 million new cancer cases and 5.07 million deaths in 2040. So, over the next few years, the market will be driven by the rise in cancer cases in China.
Additionally, the growing number of product launches in the region and the high concentration of key players in China act as major factors in driving the market. For instance, in August 2022, the cervical cancer screening test GynTect will be available to physicians and patients in China, the world's most populous country. In China, this is the first methylation test that has been approved for triage of HPV-positive cases.
Because of all of these factors, the market segment is expected to grow a lot in China over the next few years.
